Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 2011. The report details a specific share repurchase transaction executed on September 14, 2011, pursuant to shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,500,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,288 pence per share; lowest price paid was 1,277.5 pence per share.
- Treasury Holdings: Following cancellation, the Company holds 505,396,816 shares in Treasury.
- Treasury Percentage: Represents 9.06% of total issued share capital and 9.97% of total voting rights.
- Shares in Issue: 5,070,529,351 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of the Company's issued share capital through the purchase and subsequent cancellation of 1,500,000 shares. This transaction increased the proportion of Treasury shares held by the Company relative to total voting rights.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer to purchase securities.
Investor Verification Points
- Verify the total number of shares in issue (5,070,529,351) for calculating disclosure thresholds under FSA rules.
- Confirm the updated Treasury share count (505,396,816) and its impact on voting rights (9.97%).
- Note that the repurchase price range (1,277.5 to 1,288 pence) reflects market conditions on September 14, 2011.